Michael Donovan
Papers
5
Total Citations
168
H-Index
3
About
Michael Donovan is a pioneering translational researcher at the intersection of precision oncology and immunotherapy, with key contributions in personalized cancer modeling and rare tumor therapeutics. His most impactful work involves developing *Drosophila*‑based personalized platforms to identify effective drug combinations for patients with limited options. In a landmark 2019 study (107 citations), his team created a robotics‑driven screen using engineered flies to discover that trametinib plus zoledronate produced a significant 11‑month response in a patient with KRAS‑mutant metastatic colorectal cancer. He extended this approach to adenoid cystic carcinoma (2021, 38 citations), demonstrating the platform’s versatility for rare cancers where conventional therapies often fail. Donovan also advanced immunotherapy for HPV‑positive oropharyngeal cancer, leading a “window of opportunity” trial (2016, 19 citations) that used an HPV E7‑expressing *Listeria*‑based vaccine (ADXS11‑001) before robotic surgery. This work showed enhanced HPV‑specific T‑cell immunity and shifts in T‑cell diversity, highlighting his ability to bridge preclinical discovery with early‑phase clinical testing. By combining innovative model systems with rigorous clinical translation, Donovan’s research offers new hope for patients with hard‑to‑treat malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5